Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Food or edible as carrier for pharmaceutical
Reexamination Certificate
2006-04-28
2011-11-08
Wax, Robert A (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Food or edible as carrier for pharmaceutical
C424S523000, C424S195170, C514S078000, C435S128000, C554S078000
Reexamination Certificate
active
08052992
ABSTRACT:
Disclosed herein is a lipid preparation, said preparation comprising a phosphatidylserine moiety, and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and/or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. Said lipid preparations are particularly useful in the treatment of mental and cognitive disorders, e.g. ADHD (attention deficit hyperactivity disorder) and Alzheimer's disease.The disclosed preparations present improved bioactivity, and are useful in the treatment of various cognitive and mental conditions and disorders, as well as for maintenance of normal functions of brain-related systems and processes.
REFERENCES:
patent: 5015483 (1991-05-01), Haynes et al.
patent: 5502077 (1996-03-01), Breivik et al.
patent: 5700668 (1997-12-01), De Ferra et al.
patent: 5750572 (1998-05-01), Bruzzese
patent: 5925669 (1999-07-01), Katz et al.
patent: 6005004 (1999-12-01), Katz et al.
patent: 6514973 (2003-02-01), Buchholz et al.
patent: 6541043 (2003-04-01), Lang
patent: 6645742 (2003-11-01), De Ferra et al.
patent: 2002/0091103 (2002-07-01), Stoll et al.
patent: 2004/0120985 (2004-06-01), Geiss
patent: 2004/0234587 (2004-11-01), Sampalis
patent: 2005/0130937 (2005-06-01), Ben Dror et al.
patent: 2006/0241080 (2006-10-01), Dror et al.
patent: 2007/0160659 (2007-07-01), Plat et al.
patent: 2008/0085319 (2008-04-01), Dror et al.
patent: 2008/0085320 (2008-04-01), Dror et al.
patent: 2009/0074857 (2009-03-01), Dror et al.
patent: 2907778 (1979-08-01), None
patent: 199 17 249 (2000-07-01), None
patent: 199 43 198 A 1 (2001-04-01), None
patent: 0209037 (1987-01-01), None
patent: 0275224 (1993-07-01), None
patent: 0275005 BI (1993-08-01), None
patent: 0 609 078 (1994-01-01), None
patent: 0609078 (1994-01-01), None
patent: 0819760 (1998-01-01), None
patent: 0922707 (1999-06-01), None
patent: 1213294 (2002-06-01), None
patent: 1417211 (2007-05-01), None
patent: 2088750 (1996-08-01), None
patent: 02-49723 (1990-02-01), None
patent: 03188088 (1991-08-01), None
patent: 06256179 (1994-09-01), None
patent: 06279311 (1994-10-01), None
patent: 07-17855 (1995-01-01), None
patent: 2000-516261 (2000-12-01), None
patent: 2001-122884 (2001-05-01), None
patent: 2001-354680 (2001-12-01), None
patent: 2002-241385 (2002-08-01), None
patent: WO 92/21335 (1992-12-01), None
patent: WO 96/37200 (1996-11-01), None
patent: WO 97/39759 (1997-10-01), None
patent: WO 00/23546 (2000-04-01), None
patent: WO 00/56869 (2000-09-01), None
patent: WO 01/82902 (2001-11-01), None
patent: WO 01/84961 (2001-11-01), None
patent: WO 02/102394 (2002-12-01), None
patent: WO 03/088949 (2003-10-01), None
patent: WO 2004/049907 (2004-06-01), None
patent: WO 2005/038037 (2005-04-01), None
Kidd, Parris, M., Phosphatidylserine; Membrane Nutrient for Memory. A Clinical and Mechanistic Assessment, Alternative Medicine Review, vol. 1, No. 2, 1996, pp. 70-84.
Peter A. Ahmann MD, et. al., Placebo-Controlled Evaluation of Ritalin Side Effects, Pediatrics, Jun. 1993, pp. 1101-1106, vol. 91, No. 6.
Semyon I. Aleynik et al., Polyenylphosphatidylcholine Protects Against Alcohol but Not Iron-Induced Oxidative Stress in the Liver, Alcoholism: Clinical and Experimental Research, 2000, pp. 196-206, vol. 24, No. 2.
Marabella A. Alhambra MD, et. al., EEG Biofeedback: A New Treatment Option for ADD/ADHD, Journal of Neurotherapy, 1995, pp. 39-43, vol. 1, No. 2.
American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), 1994, 4th Edition, Washington, DC.
Gwendolyn Barcelo-Coblijn et al., Modification by docosahexaenoic acid of age-induced alterations in gene expression and molecular composition of rat brain phospholipids, PNAS, Sep. 30, 2003, pp. 11321-11326, vol. 100, No. 20, The National Academy of Science of the USA.
Barkley, RA., Attention-Deficit Hyperactivity Disorder. A Handbook for Diagnosis and Treatment, 1990, Guilford Press, New York.
D. Benton et. al., The Influence of Phosphatidylserine Supplementation on Mood and Heart Rate when Faced with an Acute Stressor, Nutritional Neuroscience, 2001, pp. 169-178, vol. 4.
Arjan Blokland, PHD. et. al., Cognition-Enhancing Properties of Subchronic Phosphatidylserine (PS) Treatment in Middle-Aged Rats: Comparison of Bovine Cortex PS With Egg PS and Soybean PS Nutrition, 1999. pp. 778-783, vol. 15. Elservier Science.
Nicole Brossard et. al., Human plasma albumin transports [13C]docosahexaenoic acid in two lipid forms to blood cells, Journal of Lipid Research, 1997, pp. 1571-1582, vol. 38.
John R. Burgess et. al., Long-chain polyunsaturated fatty acids in children with attention-deficit hyperactivity disorder, Am. J. Clin. Nutri., 2000, pp. 327S-330S, vol. 71.
Irene Colquhoun et. al., A lack of Essential Fatty Acids as a Possible Cause of Hyperactivity in Children, Medical Hypotheses, 1981, pp. 673-679, vol. 7.
Julie A. Conquer et. al., Fatty Acid Analysis of Blood Plasma of Patients with Alzheimer's Disease, Other Types of Dementia, and Cognitive Impairment, Lipids, 2000, pp. 1305-1312, vol. 35, No. 12.
Marc Enslen et. al., Effect of Low Intake of n-3 Fatty Acids During Development on Brain Phospholipid Fatty Acid Composition and Exploratory Behavior in Rats, Lipids, 1991, pp. 203-208, vol. 26, No. 3.
Gordon B. Forbes, Clinical Utility of the Test of Variables of Attention (TOVA) in the Diagnosis of Attention-Deficit/Hyperactivity Disorder, Journal of Clinical Psychology, 1998, pp. 461-476, vol. 54, No. 4, John Wiley & Sons, Inc.
Charles H. Goyette et. al., Normative Data on Revised Conners Parent and Teacher Rating Scales, Journal of Abnormal Child Psychology, 1978, pp. 221-236, vol. 6, No. 2.
Pnina Green et. al., Modulation of Fetal Rat Brain and Liver Phospholipid Content by Intraamnlotic Ethyl Docosahexaenoate Administration, Journal of Neurochemistry, 1995, pp. 2555-2560, vol. 65, No. 6, Lippincott-Raven Publishers, Philadelphia.
Lawrence M. Greenberg et. al., Developmental Normative Data on the Test of Variables of Attention (T.O.V.A), J. Child Psychol. Psychiatry, 1993, pp. 1019-1030, vol. 34, No. 6.
Tomohito Hamazaki et. al., Administration of Docosahexaenoic Acid Influences Behavior and Plasma Catecholamine Levels at Times of Psychological Stress, Lipids, 1999, pp. S33-S37, vol. 34, Supplement.
Tony Hayek et. al., Increased Plasma and Lipoprotein Lipid Peroxidation in Apo E-Deficient Mice, Biochemical and Biophysical Research Communications, Jun. 30, 1994, pp. 1567-1574, vol. 201, No. 3, Academic Press, Inc.
S. Hirayama et. al., Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disroder—a placebo-controlled double-blind study, European Journal of Clinical Nutrition, 2004, pp. 467-473, vol. 58, Nature Publishing Group.
Barbara V. Howards, PHD. et. al., Low-Fat Dietary Pattern and Risk of Cardiovascular Disease, JAMA, Feb. 8, 2006, pp. 655-666, vol. 295, No. 6, American Medical Association.
FDA/ Center for Food Safety & Applied Nutrition, Final Decision Letter written by Christine L. Taylor, PHD., Phosphalidylserine and Cognitive Dysfunction and Dementia (Qualified Health Claim: Final Decision Letter), Office of Nutrition Products, Labeling and Dietary Supplements, U.S. Food & Drug Administration, May 13, 2003.
Yoko Irukayama Tomobe et. al., The Activity of Docosahexaenoic Acid (DHA)-rich Phospholipid was different from that of DHA-rich Triacylglycerol in Spontaneously Hypertensive Rats, J. Oleo Sci., 2001, pp. 945-950 (also numbered pp. 25-30), vol. 50, No. 12.
Miho Itomura et. al., The effect of fish oil on physical aggression in schoolchildren—a randomized, double-blind, placebo-controlled trial, Journal of Nutritional Biochemistry, 2005, pp. 163-171, vol. 16, Elsevier Inc.
B. L. Jorissen et. al., The Influence of Soy-derived Phosphatidylserine on Cognition in Age-Associated Memory Impairment, Nutritional Neuroscience, 2001, pp. 121-134, vol. 4.
Katbi J. Kemper, MD, MPH, Editorials, Dietary supplements for attention-deficit/hyperactivity disorde
Bar-On Zohar
Ben Dror Gai
Farkash Orly
Pelled Dori
Plat Dorit
Cooper & Dunham LLP
Enzymotec Ltd.
Sasan Aradhana
Wax Robert A
White John P.
LandOfFree
Glycerophospholipids containing omega-3 and omega-6 fatty... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glycerophospholipids containing omega-3 and omega-6 fatty..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glycerophospholipids containing omega-3 and omega-6 fatty... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4262968